Virtual Event | August 25, 2022

The Critical Differences Between Scale Up And Scale Out

Nurix Therapeutics’ Michael Blackton and Center for Breakthrough Medicines’ John Lee level-set the conversation around scale up and scale out of allogeneic and autologous therapies respectively. From ensuring product safety and efficacy to regulatory issues, Blackton and Lee explain the critical differences between scale up and scale out.

access the Virtual Event!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

Charter Medical